dm+d

Unassigned

New Medicines

Acute myeloid leukaemia (AML) - 1st-line, in pts ineligible for intensive induction therapy

Information

New molecular entity
Boehringer Ingelheim
Boehringer Ingelheim

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Yes
Yes
Jun 15Apr 15: Based on a readout of the PIII study, Boehringer Ingelheim has decided it will not submit for regulatory approval; the data will be presented at an upcoming conference later this year [9].

Category

Polo-like kinase 1 (PLK-1) inhibitor
4 April 2013The incidence of the AMLs in European adults is 5-8 cases per 100,000 [4]
Acute myeloid leukaemia (AML) - 1st-line, in pts ineligible for intensive induction therapy
Intravenous

Evidence based evaluations